These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The Association between CAG Repeat Length and Age of Onset of Juvenile-Onset Huntington's Disease. Schultz JL; Moser AD; Nopoulos PC Brain Sci; 2020 Aug; 10(9):. PubMed ID: 32825467 [TBL] [Abstract][Full Text] [Related]
3. Assessment of the Performance of a Modified Motor Scale as Applied to Juvenile Onset Huntington's Disease. Horton MC; Nopoulos P; Nance M; Landwehrmyer GB; Barker RA; Squitieri F; ; Burgunder JM; Quarrell O J Huntingtons Dis; 2019; 8(2):181-193. PubMed ID: 30856116 [TBL] [Abstract][Full Text] [Related]
4. Longitudinal Clinical and Biological Characteristics in Juvenile-Onset Huntington's Disease. Schultz JL; Langbehn DR; Al-Kaylani HM; van der Plas E; Koscik TR; Epping EA; Espe-Pfeifer PB; Martin EP; Moser DJ; Magnotta VA; Nopoulos PC Mov Disord; 2023 Jan; 38(1):113-122. PubMed ID: 36318082 [TBL] [Abstract][Full Text] [Related]
5. Dystonia-predominant adult-onset Huntington disease: association between motor phenotype and age of onset in adults. Louis ED; Anderson KE; Moskowitz C; Thorne DZ; Marder K Arch Neurol; 2000 Sep; 57(9):1326-30. PubMed ID: 10987900 [TBL] [Abstract][Full Text] [Related]
9. Comorbidities and clinical outcomes in adult- and juvenile-onset Huntington's disease: a study of linked Swedish National Registries (2002-2019). Furby H; Moore S; Nordstroem AL; Houghton R; Lambrelli D; Graham S; Svenningsson P; Petersén Å J Neurol; 2023 Feb; 270(2):864-876. PubMed ID: 36253622 [TBL] [Abstract][Full Text] [Related]
10. Interrater Reliability of the Unified Huntington's Disease Rating Scale-Total Motor Score Certification. Winder JY; Roos RAC; Burgunder JM; Marinus J; Reilmann R Mov Disord Clin Pract; 2018; 5(3):290-295. PubMed ID: 30363437 [TBL] [Abstract][Full Text] [Related]
11. Juvenile-Onset Huntington's Disease in Peru: A Case Series of 32 Patients. Vishnevetsky A; Cornejo-Olivas M; Sarapura-Castro E; Inca-Martinez M; Rabinowitz D; Milla-Neyra K; Mazzetti P; Bird T Mov Disord Clin Pract; 2023 Feb; 10(2):238-247. PubMed ID: 36825038 [TBL] [Abstract][Full Text] [Related]
12. Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. Moss DJH; Pardiñas AF; Langbehn D; Lo K; Leavitt BR; Roos R; Durr A; Mead S; ; ; Holmans P; Jones L; Tabrizi SJ Lancet Neurol; 2017 Sep; 16(9):701-711. PubMed ID: 28642124 [TBL] [Abstract][Full Text] [Related]
13. An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers. Vaccarino AL; Anderson K; Borowsky B; Duff K; Giuliano J; Guttman M; Ho AK; Orth M; Paulsen JS; Sills T; van Kammen DP; Evans KR; Mov Disord; 2011 Apr; 26(5):877-84. PubMed ID: 21370269 [TBL] [Abstract][Full Text] [Related]
14. Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis. Fusilli C; Migliore S; Mazza T; Consoli F; De Luca A; Barbagallo G; Ciammola A; Gatto EM; Cesarini M; Etcheverry JL; Parisi V; Al-Oraimi M; Al-Harrasi S; Al-Salmi Q; Marano M; Vonsattel JG; Sabatini U; Landwehrmeyer GB; Squitieri F Lancet Neurol; 2018 Nov; 17(11):986-993. PubMed ID: 30243861 [TBL] [Abstract][Full Text] [Related]
15. Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study. Gonzalez V; Cif L; Biolsi B; Garcia-Ptacek S; Seychelles A; Sanrey E; Descours I; Coubes C; de Moura AM; Corlobe A; James S; Roujeau T; Coubes P J Neurosurg; 2014 Jul; 121(1):114-22. PubMed ID: 24702329 [TBL] [Abstract][Full Text] [Related]
16. Comparison of the Huntington's Disease like 2 and Huntington's Disease Clinical Phenotypes. Anderson DG; Ferreira-Correia A; Rodrigues FB; Aziz NA; Carr J; Wild EJ; Margolis RL; Krause A Mov Disord Clin Pract; 2019 Apr; 6(4):302-311. PubMed ID: 31061838 [TBL] [Abstract][Full Text] [Related]
17. Rate of change in early Huntington's disease: a clinicometric analysis. Meyer C; Landwehrmeyer B; Schwenke C; Doble A; Orth M; Ludolph AC; Mov Disord; 2012 Jan; 27(1):118-24. PubMed ID: 22095693 [TBL] [Abstract][Full Text] [Related]
18. Cannabinoids for Treatment of Dystonia in Huntington's Disease. Saft C; von Hein SM; Lücke T; Thiels C; Peball M; Djamshidian A; Heim B; Seppi K J Huntingtons Dis; 2018; 7(2):167-173. PubMed ID: 29562549 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. Furr Stimming E; Claassen DO; Kayson E; Goldstein J; Mehanna R; Zhang H; Liang GS; Haubenberger D; Lancet Neurol; 2023 Jun; 22(6):494-504. PubMed ID: 37210099 [TBL] [Abstract][Full Text] [Related]
20. The Clinical Features and Progression of Late-Onset Versus Younger-Onset in an Adult Cohort of Huntington's Disease Patients. Anil M; Mason SL; Barker RA J Huntingtons Dis; 2020; 9(3):275-282. PubMed ID: 32675419 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]